Objectives: To define the population structure of extraintestinal pathogenic Escherichia coli (ExPEC) in Japan and its relationship with antimicrobial resistance and the major resistance mechanisms for fluoroquinolones and b-lactams, we designed a multicentre prospective study.
Introduction
Extraintestinal pathogenic Escherichia coli (ExPEC) is one of the most common and important causes of both community-and hospital-acquired infections. 1 The increase in antimicrobial resistance among the ExPEC population has challenged its effective treatment. Specifically, the global increase in resistance to thirdgeneration cephalosporins and fluoroquinolones poses a significant public health threat because these drugs are widely used as treatment options for serious infections. 2 The ESBLs, especially the CTX-M types, contribute to third-generation cephalosporin resistance and specific mutations in the quinolone resistancedetermining regions (QRDRs) in gyrA and parC are the main contributors to fluoroquinolone resistance. 3 The use of standardized sequence-based strain typing to define bacterial lineages, such as MLST and fumC/fimH (CH) typing, elucidated that a large proportion of antimicrobial-resistant ExPEC strains belong to a small set of clonal groups that have a worldwide distribution. 4 ,5 E. coli ST131 has been the most common pandemic clone in recent years, especially among fluoroquinolone-resistant or ESBL-producing isolates. Of the several subclonal lineages present in ST131, two subsets of the C/H30 clade (C group, defined by whole-genome-based phylogeny or fimH allele 30), i.e. the C1/H30R clade and the C2/H30Rx clade, are responsible for fluoroquinolone resistance and bla CTX-M-15 , respectively. 6, 7 It is important to understand ExPEC from a viewpoint of common clones, focusing not only on the antimicrobial-resistant ones but also on the susceptible ones. A susceptible pandemic clone, such as ST95, has maintained a large population and contributes to the burden of infections. 4 Moreover, a susceptible clone has the potential to gain resistance, becoming a prevalent clone; ST393 has continued to spread with progressive acquisition of resistance to various antimicrobials over the last 30 years. 8 Acknowledging the persistent pressure of fluoroquinolones and the success of the fluoroquinolone-resistant ST131 clone, the development of fluoroquinolone resistance within the fluoroquinolone-susceptible population is of concern. However, in contrast to the numerous efforts and attention given to ESBL producers, the fluoroquinoloneresistant population and/or ST131, studies of an entire population of ExPEC, including the antimicrobial-susceptible population without any selection criteria, are limited, and a study that investigates the relationship between the clones and the quinolone resistance mechanisms is missing. 4 To define the latest population structure of ExPEC in Japan and their relationships with antimicrobial resistance and the major resistance mechanisms for fluoroquinolones and b-lactams, we designed a multicentre prospective study that collected all of the clinical E. coli isolates over a period of time.
Materials and methods

Bacterial isolates
This study was conducted at 10 acute-care hospitals with microbiology laboratories in five prefectures located in the centre of Japan. During December 2014, all of the non-duplicate E. coli isolates obtained from the clinical specimens were sent to a reference laboratory (Kyoto University) for further investigation. Cultures for surveillance purposes and stools were excluded. The isolates were collected and saved anonymously, with only information regarding the age, sex, source and inpatient or outpatient status.
Ethics
The Ethics Committee of Kyoto University Graduate School and Faculty of Medicine approved this study (E2450) and waived the need for obtaining informed consent from each patient.
Identification and susceptibility testing
Bacterial identification was performed at each hospital using the Vitek 2 (Sysmex bioMérieux, Tokyo, Japan) or the MicroScan (Beckman Coulter K. K., Tokyo, Japan) system. Antimicrobial susceptibility was evaluated by microdilution at the reference laboratory using a Dry Plate Eiken (Eiken, Tokyo, Japan) following CLSI standards. 9 The antimicrobials tested included levofloxacin, trimethoprim/sulfamethoxazole, fosfomycin, colistin, amikacin, gentamicin, tobramycin, minocycline, cefazolin, cefmetazole, cefotaxime, ceftazidime, cefepime, aztreonam, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, imipenem and meropenem. Antimicrobial susceptibilities for ciprofloxacin and nalidixic acid were evaluated using the Etest (Sysmex bioMérieux). The results were interpreted using the 2016 CLSI breakpoints. 9 Intermediate and resistant results were analysed as nonsusceptible. MDR was defined as non-susceptible to at least one agent in three or more antimicrobial classes (piperacillin was included instead of ampicillin). 10 We defined a resistance score using the number of nonsusceptible antimicrobial classes.
Detection of clonal groups
Bacterial DNA was isolated using a QIAamp DNA Mini kit (Qiagen, Hilden, Germany). We defined clonal groups using high-resolution two-locus clonal typing (CH typing). 11 For isolates that had novel fumC alleles, MLST was performed according to the Achtman scheme (http://mlst.ucc.ie/mlst/dbs/ Ecoli) using seven housekeeping genes. 12 Isolates with an fumC or fimH allele that differed by only one nucleotide (i.e. one SNP) in comparison with an established allele reference sequence were considered to belong to the corresponding allele group. 11 To guess the STs or ST complexes (STCs) from the CH types, we constructed a correspondence table from previous studies 5, 7, [13] [14] [15] [16] 18 was used to demonstrate the relationship between the STs and to define the founder of an STC. The STCs were defined at the single-locus variant level. We also performed phylogenetic grouping of seven E. coli clades 19 and O typing using PCR detection of the rfb alleles. 20, 21 CH40-30 (indicating combination of CH alleles) isolates with the ST131 C1/ H30R or C2/H30Rx clade characteristic of a QRDR genotype 6, 7 were assessed for C2/H30Rx status by PCR detection of the ybbW SNP. 22 
b-Lactamase identification
The presence of the ESBL or plasmid-mediated AmpC b-lactamase (pAmpC) genes was defined by PCR amplification and sequencing of bla CTX-M , 23, 24 bla TEM , 25 bla SHV , 26 bla GES , 27 bla PER , 27 bla VEB , 27 bla OXA 28,29 and the six main groups of pAmpC genes, 30 as described previously.
Fluoroquinolone resistance
The QRDRs of the gyrA and parC genes and the AcrAB efflux pump regulatory genes, marOR and acrR, were sequenced and the corresponding amino acids were compared with the corresponding regions of E. coli K-12 (GenBank accession number NC000913). 31 The marOR and acrR mutations, affecting the AcrAB efflux pump and fluoroquinolone resistance, were interpreted as in Komp Lindgren et al. 32 Plasmid-mediated quinolone resistance (PMQR) determinants [qnrA, qnrB, qnrC, qnrD, qnrS, qepA, aac(6 0 )-Ib-cr and oqxAB] were detected by PCR. 33 
Statistical analysis
Categorical variables were compared using Fisher's exact test. Continuous variables were compared using the Kruskal-Wallis test or a Mann-Whitney U-test, respectively. A P value ,0.05 was considered statistically significant. We conducted our statistical analysis using Stata, version 13.1 (StataCorp, College Station, TX, USA).
Results and discussion
During the 1 month collection period in December 2014, a total of 329 non-selective clinical E. coli isolates were collected. The 329 patients included 218 females (66%) and 195 outpatients (59%). Their median age was 73 years (IQR 61-81, range 0-100). The most common source of the isolates was the urinary tract (n " 214, 65%), followed by blood culture (n " 39), intraabdominal sites (including ascites and bile, n " 19), the female genital tract (n " 18), the skin and subcutaneous tissue or pus (n " 17), the respiratory tract (n " 15) and others (n " 7).
Major clonal groups
CH typing identified 103 CH types. The most prevalent CH type was 40-30, which was present in one-quarter of the isolates (n " 83; Table 1 ). Ten other prevalent CH types were 38-41, 40-21, 35-27, 38-18, 24-30, 40-22, 38-16, 40-41, 14-64 and 26-5 (n " 8-19, each with .2% prevalence, 35% in total). These major CH types belonged to the virulent phylogenetic groups B2 and D, 34 which were also prevalent in the non-major CH types. The CH-STC database included 227 CH types and 364 STs (Dataset S1, available as Supplementary data at JAC Online), which converted 77% of CH Clone and resistance among E. coli population JAC types into 1 STC: 153 CH types were converted into 1 ST, 22 CH types were converted into 1 STC including .1 ST, and 52 CH types were converted into .1 STC (each CH type corresponded to 2-10 STCs). The common estimated STCs among the study isolates were 131, 95, 73, 357/1876, 69, 38 and 1193 (Table S1 ). All 11 major CH types were included in these seven major STCs (Table 1) . CH typing provided a greater resolution than MLST for the three most common STCs, 131, 95 and 73, which were divided into more than one CH type. This result was expected 11 and was one of the reasons why we used CH typing. STC131 included CHs 40-30, 40-22 and 40-41. All 83 CH40-30 isolates had the unique gyrA 1AB/parC 1aAB genotype. 5 Nineteen CH40-30 isolates (23%) were defined as the ST131 C2/H30Rx clade and the remaining 64 isolates were regarded as the ST131 C1/H30R clade. 6, 7 Patients with CH40-30 were older than patients with non-CH40-30 and none of the patients with CH40-30 had female genital tract infections (Table 2 ). CHs 38-41, 38-16 and 14-64 were common in outpatients, whereas CH40-22 was common in inpatients.
Antimicrobial non-susceptibility
A total of 212 (64%) isolates were non-susceptible to at least one antimicrobial and 110 isolates (33%) exhibited MDR ( Table 2 shows the major CH types and Table S1 shows the major STCs). Nonsusceptibility to quinolones (nalidixic acid, 50%; levofloxacin and ciprofloxacin, 34%) and b-lactams (piperacillin, 42%; cefazolin, 37 %) was common ( Table 2 and Figure S1 ). These rates are similar to data from a Japanese national surveillance programme in 2014 (levofloxacin, 38%; piperacillin, 46%; cefazolin, 30%) (http://www. nih-janis.jp/), which supports the validity of our strain set. Isolates non-susceptible to amikacin, imipenem or meropenem were not found and carbapenem-non-susceptible E. coli is still rare in Japan. 35 CH40-30 isolates dominated in 15 of 18 antimicrobial-nonsusceptible categories and the MDR category with 39%-75% prevalence (except minocycline, cefmetazole and colistin; Figure 1 ). The major CH types, including CH40-30, accounted for 46%-96% of each antimicrobial-non-susceptible population. A study from the USA in 2010-11 5 also found a predominance of ST131-H30 (CH40-30) in each antimicrobial-resistant population, but the prevalence rates were lower than in our data (range 11%-52%; 75% versus 52% for ciprofloxacin and 64% versus 23% for cefotaxime/ceftriaxone). CHs 38-41, 40-21, 38-18, 24-30 and 38-16 had median resistance scores of zero and more than half were susceptible to all antimicrobials ( Figure S1 and Table 2) . Recent ExPEC population-based studies indicate that common non-ST131 pandemic clonal lineages include STCs 95, 69 and 73. 4 In our study, these STCs were also common (Table S1 ). STC95 and STC69 are known to be non-MDR and resistant to trimethoprim/ sulfamethoxazole, respectively, which is true for the major CH types corresponding to them (Table S1 and Table 2 ). Other pandemic strains, such as STC393 associated with fluoroquinolone resistance and ESBLs, 4 were not found and STC127 4, 13 was not common (Table S1 ). Other major STCs in this study were 357/1876, 1193 and 38, which have already been reported outside Japan. ST357 was reported in 2% of patients with bacteraemia in a UK hospital, 36 and an ST1876 strain was isolated from healthy cow faeces. 37 ST1193 has been described as a prevalent clone following ST131 among the fluoroquinolone-resistant isolates in the USA and Australia. 38, 39 STC38 is regarded as one of the global ESBLproducing clones. 1 The largest study to investigate CH types of ExPEC (93% from urine) in the USA in 2010-11 13 found that 4 of the top 10 prevalent CH types were common to this study, including 40-30, 38-41, 35-27 and 40-41 (STCs 131, 69 and 95). Matsumura et al. 13 (68) 12 (71) 9 (69) 10 (91) 8 (80) 8 (80) 8 (89) 6 (67) 7 (88) 4 (50) 85 ( 14 (74) 7 (41) 9 (69) 6 (55) 7 (70) 8 (80) 5 (56) 6 (67) 8 (100) 5 (63) 76 (58) blood 6 (7) 2 (11) 5 (29) 2 (15) 2 (18) 2 (22) 1 (11) 19 (14) intra-abdominal 2 (2)
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The other six prevalent CH types (14-2, 24-10, 14-27, 24-9, 13-5 and 38-5) were not common in this study (n " 0-5). These facts indicate the common presence of the pandemic clones and variations in the prevalence of the other clones.
b-Lactamases
bla TEM-1 was the most prevalent b-lactamase (29%; Table 2 ). bla TEM-1 and other narrow-spectrum b-lactamases were present in 100 of the 139 piperacillin-non-susceptible isolates. CH40-30 had a higher prevalence of bla TEM-1 (42%) and bla OXA-1 (12%) than the other isolates, in accordance with previous findings. 3, 40 Our surveillance in Japan during 2010-12 showed that the ESBLand pAmpC-positive rates were 9.2% and 1.7%, respectively. 35 In this study, the positivity rate of ESBL (bla CTX-M ) doubled to 22%, but that of pAmpC (bla CMY-2 ) was unchanged (1.8%). These two b-lactamases correlated well with cefotaxime non-susceptibility (present in 75 of the 77 non-susceptible and 2 of the 252 susceptible isolates). CH40-30 dominated the cefotaxime-nonsusceptible population (64%; Figure 1 ) and the ESBL-producing isolates (70%); prevalence among the ESBL producers increased from 45% in 2012. 14 These observations suggest that CH40-30-ST131-C/H30 is responsible for the increase in ESBL producers between 2012 and 2014. bla CTX-M-27 and bla CTX-M-15 were prevalent among the CH40-30 isolates, reflecting the recent Japanese epidemiology of the ESBL-producing ST131-H30R.
14 C2/H30Rx, the global CTX-M-15-producing ST131 clade, 7,41 constituted 17 of the 18 isolates with bla CTX-M-15 and two ESBL-negative isolates.
Quinolone resistance mechanisms
The number of QRDR mutations well explained the increase in the MIC of quinolones. The MICs of nalidixic acid were within a susceptible range only when the isolates had no QRDR mutations; otherwise, they were well above the resistance criteria (Figure 2a) . The MICs of ciprofloxacin increased with the number of QRDR mutations, two mutations being associated with susceptibility and three mutations with non-susceptibility (Figure 2b) . No statistically significant MIC differences were observed with the presence of acrAB-up-regulating mutations and/or PMQR determinants, likely due to limitations in the number of isolates with these mechanisms. At least three mutations in four QRDRs, two of which must be in gyrA, are required to exceed the breakpoint for resistance. 42 acrAB-up-regulating mutations and PMQR determinants also have some effect in increasing the MIC, but these effects are not strong enough to reach the breakpoint. 43, 44 However, the early low-level resistance conferred by the QRDRs (one or two mutations), acrAB overexpression or the PMQR determinants precedes and facilitates the high-level development of resistance mediated by the QRDRs. 45, 46 The MICs of nalidixic acid and ciprofloxacin and number of QRDR mutations of each CH type are shown in Figure 3 . All of the CH40-30 and CH14-64 isolates and some other major or nonmajor CH isolates had high MICs, above the resistance criteria, and contributed to the quinolone-resistant population. Specifically, CH40-30, with four QRDR mutations, dominated the nalidixic acid-non-susceptible population (present in 50%) and the ciprofloxacin-non-susceptible population (present in 75%) (Figure 1 ). This prevalence in the latter population is similar to the (8) 1 (9) 1 (10) 1 (11) 2 (22) 4 ( 1 (5) 1 (10) 1 (11) 2 (22) All of the isolates were susceptible to amikacin, imipenem and meropenem. a P value was ,0.05 in comparison with all of the other isolates. Each P value was calculated only when the P value for all 12 groups was ,0.05. Prevalence of CH type Figure 1 . Prevalence of the major CH types in each antimicrobial-non-susceptible population. Antimicrobials and MDR status are listed on the x-axis, with the numbers of non-susceptible isolates in each category and non-susceptible rates among all of the isolates below. The 'All' column on the left shows the number of isolates belonging to each CH type. The percentages on the bars show the relative prevalence of that CH type in each category, of which the most prevalent CH type is highlighted in red; CH40-30 is highlighted with a yellow background. CH40-30 dominated in 15 of the 18 antimicrobial-non-susceptible populations and the MDR category, with a predominance of 39%-75%. The major CH types, in total, accounted for 46%-96% of each antimicrobial-non-susceptible population and 81% of the MDR population. NAL, nalidixic acid; PIP, piperacillin; CFZ, cefazolin; LVX, levofloxacin; CIP, ciprofloxacin; SAM, ampicillin/sulbactam; SXT, trimethoprim/sulfamethoxazole; CTX, cefotaxime; FEP, cefepime; ATM, aztreonam; CAZ, ceftazidime; GEN, gentamicin; MIN, minocycline; TOB, tobramycin; TZP, piperacillin/tazobactam; CMZ, cefmetazole; FOF, fosfomycin; CST, colistin. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. No statistically significant MIC differences were observed for the presence of the acrAB-up-regulating mutations and/or the PMQR determinants. One isolate had the highest MICs (nalidixic acid, 256 mg/L; ciprofloxacin, 1.5 mg/L) among the isolates without the QRDR mutation, which had both the acrAB-up-regulating mutation (frameshift mutation in acrR) and qnrB. One isolate had the lowest ciprofloxacin MIC (0.38 mg/L) among the isolates with three QRDR mutations and had an LDIV genotype of only one mutation in gyrA. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
Clone and resistance among E. coli population JAC situation in the USA in 2011 (71%) but is higher than previous data in Japan in 2009 47 (21%) and outside of Japan in 2002-07 3 (24%-44%), which suggests a recent increase of CH40-30. Fifty-three isolates (16%) with one or two QRDR mutations from eight major CH types and non-major types were associated with nalidixic acid nonsusceptibility and elevated ciprofloxacin MIC (Figure 3) .
The QRDR types are detailed in Table 3 . Eight of the major CH types had multiple QRDR types, including WT and mutants, indicating the presence of different clonal lineages in each group. The other major CHs, 40-30, 38-16 and 14-64, had only one QRDR type, indicating a tight clonal relationship. acrAB-up-regulating mutations were found in marOR (2%) and acrR (9%) ( Table 3) . aac(6 0 )-Ib-cr was the most prevalent PMQR determinant, and 12% of the CH40-30 had it; an association of ST131 with acc(6 0 )-Ib-cr was already known. 3, 40 The study limitations included the focus on b-lactamases and the major quinolone resistance mechanisms, and a lack of investigation of other mechanisms, such as acrAB expression or phenotype-based experiments for the efflux pumps. However, b-lactamases and the QRDR mutations well explained the basis for the non-susceptibility of the third-generation cephalosporins and quinolones. We could not assess the temporal trends of the clonal distributions, but the high prevalence of the ST131-C/H30 clone in our study, and data from previous studies, indicate further expansion of the ST131-C/H30 clone. The strengths included the prospective and non-selective collection of the study population and the employment of strain typing for all of the study isolates using a sequencing-based method.
Conclusions
In summary, to our knowledge, this study is the first to define a population structure of ExPEC in Japan and to elucidate the relationships between clonal groups and major resistance mechanisms. We revealed that quinolone and third-generation cephalosporin non-susceptibilities were prevalent and were largely supported by the dominance of CH40-30, i.e. the ST131-C/H30 clone (77% C1/H30R clade), which was associated with QRDR mutations and ESBLs. Moreover, CH40-30 dominated most of the antimicrobial-non-susceptible and MDR populations. Other major clones (CHs 35-27, 40-22, 40-41, 14-64 and 26-5 corresponding to the STCs 69, 131, 1193 and 38) also contributed to these populations. We elucidated that low-level fluoroquinolone-resistant isolates with one or two QRDR mutations are spreading among 
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c One isolate had both marOR and acrR mutations.
d
One CH40-30 isolate had a 9 bp insertion that resulted in four amino acid changes and one non-major isolate had a 15 bp deletion that resulted in the loss of five amino acids.
e One isolate had both aac(6 0 )-Ib-cr and qnrB.
Clone and resistance among E. coli population JAC multiple clones, including very susceptible clones. With persistent use and the pressure of quinolones, these isolates are at risk of the acquisition of resistance through additional mutations in the QRDRs, which may lead to the evolution of the fluoroquinoloneresistant clone and its subsequent expansion. The clone ST131-C/ H30 expanded greatly and rapidly after the acquisition of fluoroquinolone resistance with QRDR mutations, 48, 49 although other factors might also have contributed. 50 Further analysis and understanding of the CH40-30-ST131-C/H30 clone and close monitoring of the population structure and the quinolone resistance of ExPEC will provide important knowledge to control the increase in antimicrobial-resistant ExPECs.
